Pathogenesis of the Endometriosis-Related Ovarian Neoplasms

Molecular Pathogenesis of Gynecologic Cancer (H Katabuchi and H Tashiro, Section Editors)


Among ovarian tumors, clear cell carcinoma, endometrioid adenocarcinoma and endocervical-like mucinous borderline tumor are frequently associated with endometriosis. Clinicopathological and molecular evidences are accumulating, which suggest that most, if not all, endometriosis-related ovarian neoplasms (ERONs) arise from endometriosis. Although clear cell carcinoma, endometrioid carcinoma, and endocervical-like mucinous borderline tumor differ in their morphology and immunophenotype, recent genome-wide analyses have elucidated genetic alterations that are commonly found in ERONs. The major one is somatic mutations of a chromatin-remodeling gene ARID1A. Subsequent studies showed that ARID1A alterations occur at early stage of ERON development, leading to the notion that ARID1A plays a key role in ERON tumorigenesis. Understanding the molecular changes involved in the development of ERON, including ARID1A, is essential for future translational research that can lead to new diagnostic approaches for detection of early neoplastic changes. In this paper, recent evidences of clinicopathological and molecular features of ERONs are reviewed.


Endometriosis-related ovarian neoplasms Clear cell carcinoma Endometrioid carcinoma Endocervical-like mucinous borderline tumor ARID1A Molecular pathogenesis of gynecologic cancer Endometriosis-related ovarian neoplasms Endometriosis-related ovarian neoplasm tumorigenesis 


  1. 1.
    Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42:918–31.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol. 2002;84:399–403.PubMedCrossRefGoogle Scholar
  4. 4.
    Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Aure JC, Høeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol. 1971;37:860–7.PubMedGoogle Scholar
  6. 6.
    Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol. 2003;109:97–101.PubMedCrossRefGoogle Scholar
  7. 7.
    Kurman RJ, Craig JM. Endometrioid and clear cell carcinoma of the ovary. Cancer. 1972;29:1653–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Fukunaga M, Nomura K, Ishikawa E, et al. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology. 1997;30:249–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Erzen M, Rakar S, Klancnik B, et al. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol. 2001;83:100–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Orezzoli JP, Russell AH, Oliva E, et al. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110:336–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Komiyama S, Aoki D, Tominaga E, et al. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol. 1999;72:342–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Moriya T, Mikami Y, Sakamoto K, et al. Endocervical-like mucinous borderline tumors of the ovary: clinicopathological features and electron microscopic findings. Med Electron Microsc. 2003;36:240–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol. 2003;22:42–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Maeda D, Shih IM. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013;20:45–52.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35:199–203.PubMedCrossRefGoogle Scholar
  16. 16.
    Ushijima K. Current status of gynecologic cancer in Japan. J Gynecol Oncol. 2009;20:67–71.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Jenison EL, Montag AG, Griffiths CT, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369–74.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol. 2006;94:138–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Kennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989;32:342–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009;22:824–32.PubMedGoogle Scholar
  23. 23.
    Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol. 1996;60:412–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Sirichaisutdhikorn D, Suprasert P, Khunamornpong S. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev. 2009;10:1041–5.PubMedGoogle Scholar
  27. 27.
    Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Kobayashi H, Sumimoto K, Kitanaka T, et al. Ovarian endometrioma–risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol. 2008;138:187–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Veras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol. 2009;33:844–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.PubMedGoogle Scholar
  31. 31.
    Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77:298–304.PubMedCrossRefGoogle Scholar
  33. 33.
    Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol. 1980;23:951–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75:1023–8.PubMedGoogle Scholar
  35. 35.
    DePriest PD, Banks ER, Powell DE, et al. Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women. Gynecol Oncol. 1992;47:71–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Eifel P, Hendrickson M, Ross J, et al. Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer. 1982;50:163–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Zaino RJ, Unger ER, Whitney C. Synchronous carcinomas of the uterine corpus and ovary. Gynecol Oncol. 1984;19:329–35.PubMedCrossRefGoogle Scholar
  38. 38.
    Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol. 1985;16:28–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Kline RC, Wharton JT, Atkinson EN, et al. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol. 1990;39:337–46.PubMedCrossRefGoogle Scholar
  40. 40.
    Falkenberry SS, Steinhoff MM, Gordinier M, et al. Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. J Reprod Med. 1996;41:713–8.PubMedGoogle Scholar
  41. 41.
    Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer. 1988;61:340–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Lehman MB, Hart WR. Simple and complex hyperplastic papillary proliferations of the endometrium: a clinicopathologic study of nine cases of apparently localized papillary lesions with fibrovascular stromal cores and epithelial metaplasia. Am J Surg Pathol. 2001;25:1347–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Kim KR, Choi J, Hwang JE, et al. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology. 2010;57:587–96.PubMedCrossRefGoogle Scholar
  44. 44.
    Fukunaga M, Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod Pathol. 1998;11:784–8.PubMedGoogle Scholar
  45. 45.
    Yasunaga M, Ohishi Y, Oda Y, et al. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol. 2009;40:965–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25:83–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Halimi SA, Maeda D, Shinozaki-Ushiku A, et al. Claudin-18 overexpression in intestinal-type mucinous borderline tumour of the ovary. Histopathology. 2013.Google Scholar
  48. 48.
    Jones S, Wang TL, Shih IM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228–31.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532–43.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Huang J, Zhao YL, Li Y, et al. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes, Chromosomes Cancer. 2007;46:745–50.PubMedCrossRefGoogle Scholar
  51. 51.
    Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71:6718–27.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625–32.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010;11:5120–8.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Yamamoto S, Tsuda H, Takano M, et al. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460:77–87.PubMedCrossRefGoogle Scholar
  55. 55.
    Yamamoto S, Tsuda H, Takano M, et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25:615–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Wu CH, Mao TL, Vang R, et al. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol. 2012;31:297–303.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Samartzis EP, Samartzis N, Noske A, et al. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol. 2012;25:885–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597–601.PubMedCrossRefGoogle Scholar
  59. 59.
    McConechy MK, Ding J, Senz J, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2013.Google Scholar
  60. 60.
    Ho CM, Lin MC, Huang SH, et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. Gynecol Oncol. 2009;112:307–13.PubMedCrossRefGoogle Scholar
  61. 61.
    Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998;58:2095–7.PubMedGoogle Scholar
  62. 62.
    Catasús L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35:1360–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med. 2009;133:1775–81.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010;29:1741–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res. 2008;14:32–40.PubMedCrossRefGoogle Scholar
  66. 66.
    Liu J, Albarracin CT, Chang KH, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004;17:75–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Pathology, Graduate School of MedicineThe University of TokyoTokyoJapan

Personalised recommendations